Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Catonsville, Maryland Clinical Trials

A listing of Catonsville, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (73) clinical trials

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

This study evaluates the rate of radiological disease progression with the new 2nd generation positron emission tomography (PET) radiopharmaceutical, 18F-DCFPyL, in patients with metastatic castration (mCRPC) and non-metastatic (nmCRPC) castration resistant prostate cancer who have evidence of biochemical (PSA) disease progression without evidence of radiological disease progression on conventional standard ...

Phase

7.99 miles

Learn More »

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

MMR-deficient cancers of any histologic type appear to be very sensitive to PD-1 blockade with pembrolizumab, and similar data are also beginning to emerge for nivolumab and other immune checkpoint inhibitors. Among the MMR-deficient cancers, the best antitumor responses are often associated with high microsatellite instability (MSI-H status), higher tumor ...

Phase

7.99 miles

Learn More »

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

The trial will enroll up to 90 patients, 30 for each cohort. Eligible patients will continue on androgen ablative therapy with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron) if not surgically castrated to suppress endogenous testosterone production. Patients will also receive intramuscular injection with either testosterone cypionate or testosterone ...

Phase

8.06 miles

Learn More »

Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

Radiation therapy is an effective and frequently utilized modality for the treatment of clinically localized prostate cancer. Traditionally, external beam radiation has been delivered in a fractionated manner using daily doses of 1.8-2.0 Gy. This daily dose was derived from early animal experiments and clinical experience, supported by mathematical models ...

Phase

8.06 miles

Learn More »

Abiraterone/Prednisone Olaparib or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC). Patients with tumors that have ATM, BRCA1 and/or BRCA2 mutations/deletions/loss of heterozygosity will be randomized in a 1:1:1 fashion to each arm. Patients with mutations in noncanonical DNA repair genes ...

Phase

8.06 miles

Learn More »

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

This is an open label, non-randomized, Phase I, dose escalation/dose expansion study of PCUR-101 in combination with androgen suppression therapy in the patients with metastatic CRPC

Phase

8.06 miles

Learn More »

A Survivorship Care Plan and Embedded Navigation Tool

This is a parallel group, multisite prospective clinical study. The purpose of this study is to evaluate whether ASCENT enables patients to adhere to the survivorship guidelines and improves coordination of care to address patient needs.

Phase N/A

8.06 miles

Learn More »

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy With Integrated Biomarker Analysis

The proposed study is an open-label single-arm phase II trial. Eligible patients are those with non-metastatic biochemically-recurrent prostate cancer and a PSADT of 6 months and a minimum PSA of 1.0. After enrollment, patients will be treated with olaparib at the established dose of 300mg tablets by mouth twice daily. ...

Phase

8.06 miles

Learn More »

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive Metastatic Castration Resistant Prostate Cancer

This Phase 1/2 study is intended to investigate the safety, tolerability, and radiation dosimetry of 177Lu-PSMA-R2 and further assess preliminary efficacy data in patients with metastatic castration-resistant prostate cancer (mCRPC). The Phase 1 portion of the study will determine the recommended dose of 177Lu-PSMA-R2 for radio-ligand therapy (RLT) of mCRPC, ...

Phase

8.06 miles

Learn More »

COMbination of Bipolar Androgen Therapy and Nivolumab

The trial will enroll up to 44 participants. Eligible participants will continue on androgen ablative therapy with a GnRH analogue (i.e. Zoladex, Trelstar, Eligard, or Lupron) if they have not undergone orchiectomy. Following enrollment, participants will receive an intramuscular injection of testosterone cypionate 400mg every 4 weeks for a lead-in ...

Phase

8.06 miles

Learn More »